ALGS
Aligos Therapeutics, Inc.11.47
-0.53-4.42%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
70.58MP/E (TTM)
-Basic EPS (TTM)
-13.54Dividend Yield
0%Recent Filings
10-K
FY2025 results
Aligos Therapeutics posted FY2025 results reflecting clinical-stage biotech realities: recurring operating losses and negative cash flows that raise substantial doubt on going-concern status, with no revenue from product sales and expectations of further losses ahead. No quarterly breakdowns or Q4 metrics disclosed in the 10-K, leaving annual trends opaque; the filing flags $9.0 million milestone paid to Emory in August 2025 for pevifoscvir sodium's Phase 2 start, yet no topline/profitability figures or y/y deltas provided. Liquidity strains from R&D on HBV, MASH/obesity, and coronavirus candidates persist without debt or capex details. No annual guidance issued. Clinical trial delays from enrollment hurdles or third-party failures threaten momentum.
8-K
Aligos cuts losses, advances HBV trial
8-K
Aneja named Principal Accounting Officer
Aligos Therapeutics appointed Nikhil Aneja as Principal Accounting Officer on January 29, 2026, effective immediately, succeeding Lesley Ann Calhoun who remains EVP, COO, and CFO. Aneja, 49, joined as VP Finance in February 2024 with prior controller roles at CareDx and biopharma firms. Leadership stays steady.
8-K
Aligos Q3 loss widens on R&D
Aligos Therapeutics reported Q3 2025 net loss of $31.5 million, up from $19.3 million last year, driven by $23.9 million in R&D expenses for the pevifoscorvir sodium Phase 2 trial, now enrolling in multiple countries. Cash reserves hit $99.1 million, funding operations into Q3 2026. Pipeline advances include Phase 1 data presentations at The Liver Meeting and preclinical synergy for ALG-055009 in obesity combos. Yet risks loom in drug development timelines.
10-Q
Q3 FY2025 results
Aligos Therapeutics posted a Q3 net loss of $31.5M, up from $19.3M a year earlier, driven by $23.9M in R&D spend versus $16.8M last year, while revenue from customers dipped to $0.7M from $1.3M. Operating loss widened to $28.4M from $20.1M, but a $4.2M hit from the 2023 warrants fair value change dragged net results lower—yet YTD through September, the company swung to a slim $4.3M net loss from $49.1M last year, thanks to a $59.0M warrants gain. Cash swelled to $99.1M after a February 2025 PIPE netting $101.4M, funding ops into Q3 2026. No non-GAAP metrics disclosed in the 10-Q. Clinical trial delays from enrollment hurdles or regulatory snags remain a key risk.
ABUS
Arbutus Biopharma Corporation
4.59-0.36
AGNPF
Algernon Pharmaceuticals Inc.
0.06-0.00
AIM
AIM ImmunoTech Inc.
1.38+0.06
ALT
Altimmune, Inc.
5.03-0.25
ASMB
Assembly Biosciences, Inc.
33.50-1.10
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
KROS
Keros Therapeutics, Inc.
21.53+0.30
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
VIR
Vir Biotechnology, Inc.
6.48-0.24
VIRX
Viracta Therapeutics, Inc.
0.01+0.00